XOMA Earns $10 Million Milestone Payment as Another of its Licensed Assets Advances into Clinical Development May 18, 2017 7:00am EDT
XOMA to Present New Strategic Initiatives at the UBS Global Healthcare Conference May 15, 2017 4:05pm EDT
XOMA Announces Positive Results from its Phase 2 Proof-Of-Concept Study of Prolactin Inhibition Apr 24, 2017 7:00am EDT
XOMA to Present Preclinical Data from its PTH1R Monoclonal Antibodies Program at the American Association for Cancer Research Annual Meeting Mar 28, 2017 7:00am EDT
XOMA Announces Full Repayment of Hercules Technology Growth Capital Debt Obligation Mar 22, 2017 7:00am EDT
XOMA to Announce Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call Focused on its New Strategic Direction on March 16, 2017 Mar 14, 2017 7:00am EDT
